Close Menu

CHICAGO (Precision Oncology News) – Members of an international team have identified an overall survival advantage associated with adding the CDK4/6 inhibitor ribociclib (Kisqali from Novartis) to endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer, according to clinical trial data presented at the American Society for Clinical Oncology annual meeting here this weekend.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.